180 related articles for article (PubMed ID: 36054300)
1. Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.
Chen L; Liu Z; Tang H; Zhou Z; Chen J; Ma Z; Deng M; Li X; Wu Y; Zheng L; Zhou L; Zheng X; Liu Z
Cell Prolif; 2022 Dec; 55(12):e13325. PubMed ID: 36054300
[TBL] [Abstract][Full Text] [Related]
2. ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
Jiang YK; Shuai YJ; Ding HM; Zhang H; Huang C; Wang L; Sun JY; Wei WJ; Xiao XY; Jiang GS
Curr Med Sci; 2023 Jun; 43(3):560-571. PubMed ID: 37142816
[TBL] [Abstract][Full Text] [Related]
3. Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits.
Yang Q; Xu P; Liu Q; Hu F; Xie X; Jiang L; Bi R; Wang L; Ding F; Xiao H
Life Sci; 2023 Jun; 323():121592. PubMed ID: 36934972
[TBL] [Abstract][Full Text] [Related]
4. The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells.
Ren D; Li L; Wang S; Zuo Y
Tissue Cell; 2023 Jun; 82():102096. PubMed ID: 37201439
[TBL] [Abstract][Full Text] [Related]
5. USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer.
Man X; Piao C; Lin X; Kong C; Cui X; Jiang Y
J Exp Clin Cancer Res; 2019 Jun; 38(1):259. PubMed ID: 31200745
[TBL] [Abstract][Full Text] [Related]
6. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
9. LncRNA PVT1 promotes bladder cancer progression by forming a positive feedback loop with STAT5B.
Li Z; Fu H; Liu J; Song W; Zeng M; Wang J
Pathol Res Pract; 2023 Aug; 248():154635. PubMed ID: 37392551
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
11. A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer.
Gong P; Xu R; Zhuang Q; He X
Biomed Pharmacother; 2020 Jun; 126():110059. PubMed ID: 32208321
[TBL] [Abstract][Full Text] [Related]
12. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
[TBL] [Abstract][Full Text] [Related]
13. miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression.
Feng C; Sun P; Hu J; Feng H; Li M; Liu G; Pan Y; Feng Y; Xu Y; Feng K; Feng Y
Int J Oncol; 2017 Jun; 50(6):2101-2112. PubMed ID: 28440444
[TBL] [Abstract][Full Text] [Related]
14. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis.
Luo G; Zhang Y; Wu Z; Zhang L; Liang C; Chen X
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):558-566. PubMed ID: 33720323
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic role of
Jin H; Ma J; Xu J; Li H; Chang Y; Zang N; Tian Z; Wang X; Zhao N; Liu L; Chen C; Xie Q; Lu Y; Fang Z; Huang X; Huang C; Huang H
Autophagy; 2021 Apr; 17(4):840-854. PubMed ID: 32116109
[TBL] [Abstract][Full Text] [Related]
16. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
[TBL] [Abstract][Full Text] [Related]
17. Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop.
Gao T; Ji Y
Urol Int; 2021; 105(9-10):891-905. PubMed ID: 34192702
[TBL] [Abstract][Full Text] [Related]
18. LncRNA TUG1 promotes bladder cancer malignant behaviors by regulating the miR-320a/FOXQ1 axis.
Tan J; Liu B; Zhou L; Gao J; Wang XK; Liu Y; Wang JR
Cell Signal; 2022 Mar; 91():110216. PubMed ID: 34920123
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer.
Ren J; Yu H; Li W; Jin X; Yan B
Br J Cancer; 2023 Jan; 128(2):232-244. PubMed ID: 36396821
[TBL] [Abstract][Full Text] [Related]
20. LncRNA
Chen D; Chen J; Gao J; Zhang Y; Ma Y; Wei W; Wei Y
Cancer Biother Radiopharm; 2020 Jun; 35(5):319-328. PubMed ID: 32412777
[No Abstract] [Full Text] [Related]
[Next] [New Search]
